"In 2022, the IMIM underwent a remarkable transformation advancing in three key pillars: obtaining competitive resources, generating knowledge and transferring it to society. Researchers have obtained funding from prestigious entities such as the European Research Council and have excelled in events such as the Marató de TV3 in the field of mental health. In addition, important discoveries have been made in immune therapies against cancer and early diagnosis of Alzheimer's disease. The institute has also expanded its patent portfolio and attracted the attention of investors, while expanding its facilities to attract more renowned researchers in the future."
Joaquín Arribas
Director of Hospital del Mar Medical Research Institute (IMIM) and Research Director of Hospital del Mar
“It is a pleasure for me to present this report with the main results of the research in our institution. These results confirm that the strategy we initiated in 2021 was the right one. It is also confirmed that our biomedical research is consolidated as a clear area of knowledge with the capacity to create and attract talent, as demonstrated by the incorporation of scientists with recognized careers, but also by the integration into the teams of young researchers with high capacities and a promising future.”
Olga Pané
MANAGER OF HOSPITAL DEL MAR-PARC DE SALUT MAR
Overview of the year
Research Programs
Relevant Projects
Clinical Trials
Publications
Core Facilities
Funding
Personnel
Communication and Public Engagement
Translational results
Biomedical Informatics
PROGRAM DIRECTOR
Mar Albà
GROUPS
6
Computational methods to understand and predict biological phenomena related to human diseases, their diagnosis and pharmacological treatment.
+ INFORMATION ►
Cancer
PROGRAM DIRECTOR
Joan Albanell
GROUPS
17
We aim to deliver innovative precision medicine and immunotherapy to cancer patients.
+ INFORMATION ►
Epidemiology and Public Health
PROGRAM DIRECTOR
Jordi Alonso
GROUPS
11
Our goal is to promote health, prevent diseases, and translate our research in clinical practice through innovative and multidisciplinary approaches.
+ INFORMATION ►
Neurosciences
PROGRAM DIRECTOR
Rafael de la Torre
GROUPS
17
We support clinical research to gain an advanced understanding of mental and neurodegenerative diseases to improve the quality of life of patients and advance the cutting edge of neuroscientific knowledge.
+ INFORMATION ►
Translational Clinical Research
PROGRAM DIRECTOR
Xavier Nogués
GROUPS
15
Our goal is to promote health, prevent diseases, and translate our research in clinical practice through innovative and multidisciplinary approaches.
+ INFORMATION ►
Monitoring of the annual objectives of the research programs
Clara Montagut
Head of the clinical and translational research lab for new therapies and biomarkers in colorectal cancer at IMIM and head of Digestive Oncology at Hospital del Mar
"It's not that the scientific community relies on us, it's that we lead the projects. They consider us a center of the highest quality."
Funding from Research Projects by Program
EPIDEMIOLOGY AND PUBLIC HEALTH
6.714.170,99€
6.714.170,99€
CANCER
4.589.178,56€
4.589.178,56€
NEUROSCIENCES
3.457.698,24€
3.457.698,24€
BIOMEDICAL INFORMATICS
3.156.096,75€
3.156.096,75€
TRANSLATIONAL CLINICAL RESEARCH
2.481.626,10€
2.481.626,10€
OTHER (HOSPITAL AND MANAGEMENT)
230.819,20€
230.819,20€
Number of Research Projects by Program and Gender
Epidemology and Public Health
13
Total of projects
9
Led by men
4
Led by women
Translational Clinical Research
16
Total of projects
9
Led by men
7
Led by women
Cancer
21
Total of projects
14
Led by men
7
Led by women
Neurosciences
20
Total of projects
14
Led by men
6
Led by women
Biomedical Informatics
5
Total of projects
1
Led by men
4
Led by women
Other (Hospital and Management)
1
Total of projects
1
Led by men
Total competitive research projects
Total other research contracts
Outstanding Projects
INSCRIPTION
Gabriel Santpere
Head of the Neurogenomics research group at IMIM
INSCRIPTION is an innovative project whose main objective is to anticipate and predict the risk of developing psychotic disorders. We will use personalized information from genetics, brain images, and characteristics of the olfactory epithelium, which will allow us to conduct a comprehensive and accurate analysis of vulnerability to these disorders. This unique interdisciplinary approach will enable us to gather and analyze data from multiple fields to better understand the risk factors and individual characteristics that contribute to psychotic disorders. This will not only allow us to predict the risk of developing these conditions but also design prevention and treatment strategies tailored to each individual.
MORE INFO
LIVERATION
Patricia Sánchez
researcher of the Ablative therapies in oncology surgery research group at IMIM and surgery assistant physician at Hospital del Mar
LIVERATION is a Horizon Europe-Cancer mission project that aims to conduct an ambitious, pragmatic multicenter clinical trial with 720 patients with liver metastases (CRLM) and hepatocellular carcinoma (HCC) at 24 clinical centres in 6 different countries to determine whether additional ablated margin produced by radiofrequency can decrease the recurrence rate and improve patient survival. We will also evaluate the patient-centredness of the intervention and its comparativeness with other therapeutic alternatives in terms of quality of life and patient experience in real-world settings.
PERMANENS
Philippe Mortier
Researcher of the Health services research group at IMIM
Clinical management of patients with suicide risk is a challenging task, in part because suicide represents highly complex difficult-to-predict behaviour. The PERMANENS project will develop a prototype of a Clinical Decision Support System (CDSS), i.e., a medical software programme that assists clinicians in the personalised management of suicide risk. Using machine learning-based algorithms, the CDSS will enable accurate suicide risk prediction and the subsequent personalised allocation of evidence-based treatment. Data for the project will be obtained from population-representative electronic registries from Ireland, Norway, Sweden, and Catalonia (Spain). To maximize its clinical usefulness, the CDSS prototype will be co-created with both patients and clinicians through user-oriented qualitative implementation research.
MENTBEST Study
Benedikt Lorenz Amann
Researcher of the Mental Health Group at IMIM and psychiatrist at the Institute of Neuropsychiatry and Addictions of the Hospital del Mar.
MENTBEST is H2020 EU funded project that aims to mitigate the negative impacts of transformation and seize new opportunities: Global trends such as war, economic crisis, climate change, migration, digitalization, pandemics, ageing and demographic change, place increasing stress and pressure on European societies to adapt to fast-changing situations.
MORE INFO
DECONFUSID
Andrea Cerutti
Head of the B Cell Biology research group at IMIM
B cells are an important component of our immune system that fight against harmful invaders. After interacting with T follicular helper cells, they differentiate into plasma cells to produce antibodies. This process involves somatic hypermutation for improving antibody's affinity for the antigen, and class-switching to differentiate its effector function and site of action. Class-switched antibodies (IgG, IgA, IgE) have special functions different from those of IgM. Apart from neutralizing the invaders directly, antibodies also cooperate with other myeloid or lymphoid cells to clear the antigens out. In addition to the well-known antibody types (IgM, IgG, IgA, IgE), we can also distinguish IgD, mostly known from its role as a B cell receptor function. Although it also exists in a secreted form, its exact function is still not fully understood. Early research suggested it might not be essential, as mice without IgD didn't show major phenotypic manifestations, and it seemed to overlap in function with IgM. However, more research is needed to fully understand IgD's role in our immune system.
Miguel Pera
Chief Medical Officer and Chair of Surgery at Hospital del Mar- Parc de Salut MAR
"Clinical trials represent one of the most valuable forms of research as they serve as the gateway to the final transfer of previous research findings into clinical practice."
Clinical Trials Signed in 2022
2
EPIDEMIOLOGY AND PUBLIC HEALTH
57
TRANSLATIONAL CLINICAL RESEARCH
68
CANCER
20
NEUROSCIENCES
16
OTHER (HOSPITAL AND MANAGEMENT)
TOTAL
163
Clinical trials 2018-2022
Relevant Clinical Trials
A phase Ib study with a safety lead-in cohort and expansion phase, of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer
Maria Martinez-Garcia, Researcher of the Molecular cancer therapeutics group at IMIM and chief of the oncology section.
Breast cancer is the second most common invasive malignancy and the leading cause of cancer-related mortality in women. Metastatic breast cancer presents poor prognosis. Overexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 20% of breast cancers. Several agents are approved for the treatment of HER2 positive breast cancer. There are no data to support a specific treatment after progression on approved targeted therapies, and new therapies are still needed for these refractory patients. This is a proof-of-concept phase I clinical trial for patients with HER2 positive metastatic breast cancer refractory to antiHER2 therapies, to test the infusion of allogenic NK cells (Investigational Cellular Therapy Product [ICTP]) in order to enhance the ADCC of trastuzumab and pertuzumab to overcome this resistance and improve clinical outcome. The hypothesis of the trial is that the effect of trastuzumab and pertuzumab can be improved by regulating the efficiency of the ADCC activity through the infusion of ex-vivo activated allogenic NK cells
Protocol for Clinical Trials targeting macro-, micro-immuno-thrombosis, vascular hyperinflammation, and hypercoagulability and renin-angiotensin-aldosterone system (RAAS) in hospitalized patients with COVID-19.
Roberto Güerri, researcher of the Infectious Pathology and Antimicrobials research group at IMIM and Head of section at the Infectious Diseases Service of Hospital del Mar.
This is a clinical trial to evaluate the efficacy of drugs that modulate tissue response in hospitalized patients with COVID-19. The therapeutic objectives sought are to accelerate recovery and prevent progression to critical illness. The drugs under study include experimental drugs (TXA127, TRV027) and a monoclonal antibody used for the treatment of immune thrombocytopenia (fostamatinib). All of these drugs have mechanisms of action that act on the mechanisms of thrombosis, inflammation and hypercoagulability all of which contribute to the severity of the disease.
The clinical evaluation of the effects of AEF0217 in Down Syndrome Subjects.
Ana Maria Aldea, Head of the Clinical Research Unit and Rafael de la Torre Head of the Integrative Pharmacology and Systems Neurosciences Research Group at IMIM.
First time that the molecule AEF0217 designed to improve cognitive function in Down syndrome (DS), will be administered to subjects with DS, to test the safety/tolerability, the pharmacokinetics and have a preliminary prove of efficacy of the drug. Results are expected in the first trimester 2024.
Xosé R. Bustelo
Csic Research professor, Salamanca Cancer Research Center (csic-University of Salamanca). Vice-director, Salamanca Cancer Research Center. Coordinator, mechanisms of tumor progression program of the spanish network for biomedical research in cancer (ciberonc)
"In 2022, the IMIM has demonstrated an exceptionally high-quality scientific productivity and impact, as evidenced by its contributions to internationally renowned journals such as Nucleic Acids Research, Blood, Nature Cancer, and the Journal of the American College of Cardiology, among others."
Publications by program 2021-2022
EPIDEMIOLOGY AND PUBLIC HEALTH
TRANSLATIONAL CLINICAL RESEARCH
CANCER
NEUROSCIENCES
BIOMEDICAL INFORMATICS
HOSPITAL PROGRAMS AND OTHERS
TOTAL INDEXED PUBLICATIONS
2021
TOTAL PUBLICATIONS
994
2022
TOTAL PUBLICATIONS
966
NOTE: Indexed publications are shown, only taking into account original articles and reviews by authors who are part of the Institute.
2021
583
1st quartile
235
1st decile
2022
565
1st quartile
245
1st decile
Publications by types
2021
96
Review
64
Notes
898
Original
24
Editorial
2022
77
Review
59
Notes
889
Original
11
Editorial
Relevant Publications
Biomedical Informatics
Torrens-Fontanals M, Peralta-García A, Talarico C, Guixà-González R, Giorgino T, Selent J. SCoV2-MD: a database for the dynamics of the SARS-CoV-2 proteome and variant impact predictions. Nucleic Acids Res. 2022 Jan 7;50(D1):D858-D866.
De la Rubia I, Srivastava A, Xue W, Indi JA, Carbonell-Sala S, Lagarde J, Albà MM, Eyras E. RATTLE: reference-free reconstruction and quantification of transcriptomes from Nanopore sequencing. Genome Biol. 2022 Jul 8;23(1):153.
Montañés JC, Huertas M, Moro SG, Blevins WR, Carmona M, Ayté J, Hidalgo E, Albà MM. Native RNA sequencing in fission yeast reveals frequent alternative splicing isoforms. Genome Res. 2022 May 26;32(6):1215–27.
Gray, B*, Baruteau, A-E*, Antolin, A, Pittman, A, Sarganas, G, Molokhia, M, Blom, M T, Bastiaenen, R, Bardai, A, Priori, S G, Napolitano, C, Weeke, P E, Shakir, S A, Haverkamp, W, Winkel, B, Witney, A A, Chis-Ster, I, Sangaralingam, A, Camm, A J, Tfelt-Hansen J, Roden DM, Tan, H L, Garbe, E, Sturkenboom, M, Behr, E-R, Mestres J. Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome. Circ Genom Precis Med 2022; 15(1).
Morales A, Nerin F, Aranda D, Dieguez M, Medel B, Torrens M, Peralta A, Selent J*. In Silico Study of Allosteric Communication Networks in GPCR Signaling Bias. Int J Mol Sci 2022; 23(14): 7809.
Cancer
Galindo M, Lutfi N, Bonnin S, Martinez C, Velasco T, Garcia V, Martín-Caballero J, Ampurdanés C, Gimeno R, Colomo L, Roue G, Guilbaud G, Dantzer F, Navarro P, Murga M, Fernández-Capetillo O, Bigas A, Menendez P, Sale J, Yélamos J*. Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice. Blood 2022; 139(2): 228-239.
Pérez I, Rozalen C, Palomeque JA, Sangrador I, Dalmau M, Comerma L, Hernández A, Casadevall D, Menéndez S, Liu DD, Shen M, Berenguer J, Rius Ruiz I, Peña R, Montañés J, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J*, Celià-Terrassa T*. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nat Cancer . 2022; 3(3): 355-370.
Solé L, Lobo T, Alvarez D, Alonso J, Guillén Y, Guix M, Sangrador I, Rozalen C, Vert A, Barbachano A, Lop J, Salido M, Bellosillo B, Garcia-Romero R, Garrido M, González J, Martínez-Iniesta M, López-Arribillaga E, Salazar R, Montagut C, Torres F, Iglesias M, Celià-Terrassa T, Muñoz A, Villanueva A, Bigas A*, Espinosa L*. p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis. Nat Commun 2022; 13(1): 2866.
Rivas EI, Linares JL, Zwick M, Gómez-Llonin A, Guiu M, Labernadie A, Badia J, Lladó A, Bardia L, Pérez I, Martínez-Ciarpaglini C, Tarazona N, Sallent A, Garrido M, Celià-Terrassa T, Burgués O, Gomis RR, Albanell J, Calon A*. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors. Nat Commun 2022; 13(1): 5310.
Duro S, Nadal-Serrano M, Lalinde M, Arenas EJ, Bernardó-Morales C, Morancho B, Escorihuela M, PÉREZ S, Escrivá-de-Romaní S, Gandullo-Sánchez L, Pandiella A, Esteve-Codina A, Rodilla V, Dijcks FA, Dokter WHA, Cortés J, Saura C, Arribas J*. Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer. Cancer Res 2022; 82(24):4670-4679.
Epidemiology and Public Health
Lázaro López I, Lupón J, Cediel G, Codina P, Fitó Colomer M, Domingo M, Santiago-Vacas E, Zamora E, Sala-Vila A*, Bayés-Genís A*. Relationship of Circulating Vegetable Omega-3 to Prognosis in Patients With Heart Failure. J Am Coll Cardiol 2022; 80(18): 1751-1758.
Ramon J, Llauradó G*, Güerri-Fernández R, Climent E, Ballesta S, Benaiges D, Lopez Montesinos I, Navarro H, Fernandez N, Carrera MJ, Mauricio D, Flores JA, Chillarón JJ. Acute-to-Chronic Glycemic Ratio as a Predictor of COVID-19 Severity and Mortality. Diabetes Care 2022; 45(1): 255-258.
Llauradó G*, Amigó N, Fuertes-Martín R, Romero A, Cano A, Albert L, Giménez-Palop O, Berlanga E, Fernández-Veledo S, Correig X, Vendrell J, González-Clemente JM*. Measurement of Serum N-Glycans in the Assessment of Early Vascular Aging (Arterial Stiffness) in Adults With Type 1 Diabetes. Diabetes Care 2022; 45(10):2430-2438
Porta M*, Gasull M, Pumarega JA, Kiviranta H, Rantakokko P, Raaschou-Nielsen O, Bergdahl IA, Sandanger TM, Agudo A, Rylander C, Nøst TH, Donat-Vargas C, Aune D, Heath AK, Cirera L, Goñi-Irigoyen F, Alguacil J, Gimenez À, Tjønneland A, Sund M, Overvad K, Mancini FR, Rebours V, Boutron-Ruault MC, Kaaks R, Schulze MB, Trichopoulou A, Palli D, Grioni S, Tumino R, Naccarati A, Panico S, Vermeulen R, Quirós JR, Rodriguez-Barranco M, Colorado-Yohar SM, Chirlaque M, Ardanaz E, Wareham N, Key T, Johansson M, Murphy N, Ferrari P, Huybrechts I, Chajes V, Gonzalez CA, Bueno de Mesquita B, Gunter M, Weiderpass E, Riboli E, Duell EJ, Katzke V, Vineis P. Plasma concentrations of persistent organic pollutants and pancreatic cancer risk. Int J Epidemiol 2022; 51(2): 479-490.
Bosch-Duran G, Posso Rivera M*, Louro J, Román M, Porta M, Castells X, Macià F. Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study. eLife 2022; 11: e77434.
Neurosciences
Barrera-Conde M, Veza-Estévez E, Gomis-Gonzalez M, Garcia-Quintana J, Trabsa A, Martínez-Sadurní L, Pujades M, Perez V, de la Torre R, Bergé D, Robledo P. Role of cyclin-dependent kinase 5 in psychosis and the modulatory effects of cannabinoids. Neurobiol Dis. 2023 Jan;176:105942.
Pujol J, Blanco-Hinojo L, Ortiz H, Gallart L, Moltó L, Martínez-Vilavella G, Vilà E, Pacreu S, Adalid I, Deus J, Pérez-Sola V, Fernández-Candil J. Mapping the neural systems driving breathing at the transition to unconsciousness. Neuroimage. 2022 Feb 1;246:118779.
Madrid-Gambin F, Gomez-Gomez A, Busquets-Garcia A, Haro N, Marco S, Mason NL, Reckweg JT, Mallaroni P, Kloft L, van Oorsouw K, Toennes SW, de la Torre R, Ramaekers JG, Pozo OJ. Metabolomics and integrated network analysis reveal roles of endocannabinoids and large neutral amino acid balance in the ayahuasca experience. Biomed Pharmacother. 2022 May;149:112845.
Cieuta-Walti C, Cuenca-Royo A, Langohr K, Rakic C, López-Vílchez MÁ, Lirio J, González-Lamuño Leguina D, González TB, García JG, Roure MR, Aldea-Perona A, Forcano L, Gomis-Gonzalez M, Cés SV, Lacaille F, Ravel A, Mircher C, Walti H, Janel N, Dairou J, Lévy M, Durand S, Dierssen M, Sacco S, Fornell RT; PERSEUS Study Group. Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study). Genet Med. 2022 Oct;24(10):2004-2013.
Pujol J, Martínez-Vilavella G, Gallart L, Blanco-Hinojo L, Pacreu S, Bonhomme V, Deus J, Pérez-Sola V, Gambús PL, Fernández-Candil J. Effects of remifentanil on brain responses to noxious stimuli during deep propofol sedation. Br J Anaesth. 2023 Feb;130(2):e330-e338.
Translational Clinical Research
"Cerutti A*, Filipska M, Marcos X, Tacho R. Impact of the mucosal milieu on antibody responses to allergens. J Allergy Clin Immunol 2022; 150(3): 503-512.
Lazcano Uxue U, Cuadrado E*, Grau M, Subirana I, Martínez-Carbonell E, Boher-Massaguer M, Rodríguez Campello A, Giralt E, Fernández-Pérez I, Jiménez Conde J, Roquer González J, Ois A. Increased COVID-19 Mortality in People With Previous Cerebrovascular Disease: A Population-Based Cohort Study. Stroke 2022; 53(4): 1276-1284.
Crespo M*, Barrilado-Jackson A, Padilla E, Eguía J, Echeverría-Esnal D, Cao H, Faura A, Folgueiras M, Sola E, Pascual S, Barbosa F, Hurtado S, Ribera L, Río-No L, Pérez Sáez MJ, Redondo D, Pascual J, Mariscovid Research group. Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring. Am J Transplant 2022; 22(3): 786-800.
Montero MM*, Domene-Ochoa S, López Causapé C, Lopez Montesinos I, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Ferrer Alapont L, Grau S, Oliver A, Horcajada JP. Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates. Microbiol Spectr . 2022: e0089222
Falco M*, Meazza R, Alicata C, Canevali P, Muntasell A, Bottino C, Moretta L, Pende D, López-Botet M. Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes. HLA . 2022; 100(2): 107-118."
List of the total number of publications
Thesis
40
Total number of theses
Xavier Mayol
Internal Services and Research Laboratories Coordinator at IMIM
"Research support services are like an Olympic trampoline, they must have enough height to allow researchers to make a good, sometimes spectacular, leap."
422
projects
3777
transferred samples
5613
processed samples
3757
analyzed samples
13
active funded projects
36
Publications
MARBiobanc is a member of the ISCIII Biobanks and Biomodels Platform
7
Clinical trials of promoter industry
13
Non-commercial sponsor clinical trials
8
Studies other non-comercial developer designs
1209
Volunteers
The Clinical Research Unit is a member of the ISCIII SCReN Platform.
IMIM Internal Facilities
Histology
Microscopy
Radioactive Facilities
Cell-Culture Facilities
Cryopreservation Unit
Bioluminescence/Fluorescence Facility (IVIS)
Other IMIM resources
Drug Research Ethical Committee (CEIm-PSMar)
Molecular Cytogenetics (IMIM)
Quality-of-Life Questionnaires (IMIM)
Other PRBB Shared Facilities
Bioinformatics (CRG)
National Center for Genomic Analysis (CNAG-CRG)
Flow Cytometry (CRG-UPF)
PRBB Animal Experimentation Ethics Committee (CEEA- PRBB)
Biosafety Committee (CBS-PRBB)
Biomolecular Screening and Protein Technologies (CRG)
European Genome-Phenom Archives (CRG)
Genomics (CRG)
Genomics UPF
Tissue Engineering (CRG)
Mesoscopic Microscopy (EMBL)
Advanced Optical Microscopy (CRG-UPF)
Synthetic Peptides (UPF)
Proteomics (CRG-UPF)
Animal Facility
Marta López
Head of Research Grants and Contracts Office at IMIM
"Having projects with funding exceeding half a million euros is not common, so when you have 7 projects surpassing this amount in a year, you know it has been a great year!! And if among them, there is an ERC grant of more than 2 million euros and personalized medicine funding of over 5 million, it demonstrates the excellence of our researchers."
Sources of Funding
COMPETITIVE
2021
12.681.330,10€
COMPETITIVE
2022
10.583.724,01€
European Union
Other International Grants
National Grants
Public bodies of Generalitat
NON COMPETITIVE
2021
10.209.711,56€
NON COMPETITIVE
2022
9.200.101,97€
Clinical trials
Research contracts
Donations
Technology transfer
Analytics and Quality Controls
Others
TRUSTEES CONTRIBUTION
2021
3.402.097,46
2022
3.720.029,57
TOTAL
23.503.855,55€
COMPETITIVE
10.583.724,01€
10.583.724,01€
NON COMPETITIVE
9.200.101,97€
9.200.101,97€
TRUSTEES CONTRIBUTION (Generalitat de Catalunya)
3.720.029,57€
3.720.029,57€
Indirect cost by origin
TOTAL
3.713.818,22€
National Grants
994.481,31€
994.481,31€
International Grants (Including European)
661.266,82€
661.266,82€
Industry agreements (Clinical Trials Included)
2.040.999,72€
2.040.999,72€
Donation
17.070,37€
17.070,37€
Annual financial statements 2022
Outstanding Competitive Grants
CORDELIA- GWAS (Collaborative Cohorts Reassembled Data to study Mechanisms and Longterm Incidence of Chronic Diseases)
PRINCIPAL INVESTIGATOR
Jaume Marrugat. Head of the Girona Heart Registry (REGICOR) group at IMIM
BUDGET
4.848.615 €
PERIOD
01/01/2023 - 31/12/2025
PROJECT
Instituto de Salud Carlos III
NovoGenePop: Deciphering de novo gene birth in populations
PRINCIPAL INVESTIGATOR
Mar Albà. Head of the Evolutionary Genomics group at IMIM
BUDGET
2.453.751 €
PERIOD
1/06/2022 - 31/05/2027
PROJECT
European Research Council Advanced Grants
Vanesa Nogales
Deputy Director, IMIM
"We are committed to young scientific talent, destined to revolutionize future research, and to attracting established and internationally recognized researchers."
Personnel
Total 735
TRANSLATIONAL CLINICAL RESEARCH
207,00
207,00
CANCER
166,00
166,00
NEUROSCIENCES
156,00
156,00
EPIDEMIOLOGY AND PUBLIC HEALTH
99,00
99,00
MANAGEMENT
42,00
42,00
BIOMEDICAL INFORMATICS
33,00
33,00
HOSPITAL
17,00
17,00
CORE FACILITIES
15,00
15,00
Researchers Type by Gender
WOMEN
(243)
(243)
MEN
(190)
(190)
TOTAL
(433)
(433)
Researcher
Collaborating researcher
Postdoctoral researcher
Predoctoral researcher
Researchers Profile by Gender
WOMEN
(243)
(243)
MEN
(190)
(190)
TOTAL
(433)
(433)
R4 Leading Researcher
R3 Established Researcher
R2 Recognized Researcher
R1 First Stage Researcher
Research personel funded
25
Women
28
Men
Total 53
Jordi Alonso
Director of the Epidemiology and Public Health Program at IMIM
"In the world of research, we are interested in stepping out of the laboratories and bringing our work closer to the people who are actually the subjects of our studies."
Media
2021
PRESS RELEASES
27
NEW APPEARANCES
1828
Web
1471
1471
Press
233
233
Radio
89
89
TV
35
35
2022
PRESS RELEASES
23
NEW APPEARANCES
2005
Web
1648
1648
Press
246
246
Radio
80
80
TV
31
31
Most significant media appearances
A new study identifies two biomarkers in the blood that better capture early signs of Alzheimer's
Marc Suárez-Calvet, Head of the Fluid Biomarkers and Translational Neurology research group at IMIM and assistant neurologist at Hospital del Mar
TV3
First clinical trial of a new drug to improve the cognitive function of people with Down syndrome
Rafael de la Torre, Director of the Neurosciences Program at IMIM
TV3
Researchers discover the mechanism by which tumor cells become resistant to chemotherapy in colorectal cancer
Alexandre Calon and Jennifer Linares, Head of the Translational Research in tumor Microenvironment Group at IMIM and researcher at the same group.
TVE 1
Having suffered trauma during childhood triples the risk of suffering a serious mental disorder in adulthood
Benedikt Amann, Researcher of the Mental Health Group at IMIM and psychiatrist at the Institute of Neuropsychiatry and Addictions of the Hospital del Mar
TV3
A diet rich in plant-based omega-3 is associated with better outcomes in heart failure patients
Aleix Sala and Iolanda Lázaro, Researcher of the Cardiovascular Risk and Nutrition Group at IMIM
TV3
Our biological age, modulated by living habits, influences brain ageing beyond our chronological age
Jordi Jiménez Conde, Head of the Neurovascular Research Group at IMIM and assistant neurologist at Hospital del Mar
La Vanguardia
Website and Social Media
WEB VISITS
324.967
FOLLOWERS
10.047
NEW FOLLOWERS
793
TOP TWEET (IMPRESSIONS)
10.752 
FOLLOWERS
10.490
TOP PUBLICATION (IMPRESSIONS)
Number of scientific sessions and workshops
89
scientific sessions and workshops
Outreach
CAMPAIGNS
International Day of Women and Girls in Science (She Inspired me) - 11 February
Objective: Campaign to raise the visibility of women in science. At the IMIM we are once again celebrating the International Day of Women and Girls in Science and supporting the #SheInspiredMe campaign.
AUDIOVISUAL CONTENT:
Creation of 6 videos with 1.363 views
SOCIAL MEDIA:
12 tweets with 12.000 impressions
5 posts with 970 likes and 35.000 impressions
MORE INFO
Creation of 6 videos with 1.363 views
SOCIAL MEDIA:
12 tweets with 12.000 impressions 5 posts with 970 likes and 35.000 impressions
International Clinical Trials Day - 20 May
Objectives: Campaign to improve public awareness of clinical trials and to recruit volunteers to participate in clinical trials.
SOCIAL MEDIA:
1 post with 66 likes and 2000 impressions
8 tweets with 2.000 impressions
MORE INFO
1 post with 66 likes and 2000 impressions 8 tweets with 2.000 impressions
World Cancer Research Day - 24 September
Objectives: Campaign to raise awareness of the need for cancer research and to highlight the research work carried out by IMIM researchers.
SOCIAL MEDIA:
2 tweets with 577 impressions.
1 post with 124 likes and 3.399 impressions.
MORE INFO
2 tweets with 577 impressions. 1 post with 124 likes and 3.399 impressions.
ACTIVITIES FOR THE GENERAL PUBLIC
"Our brain, this great unknown", cycle of talks in libraries
Objective: To organize a cicle of talks in the libraries in order to bring the latest scientific advances to the general public through the best experts from Hospital del Mar and IMIM and thus to promote scientific culture and facilitate knowledge. In this edition the cycle of talks was about the brain.
AUDIOVISUAL CONTENT:
Creation of 8 videos with 185 views
SOCIAL MEDIA:
19 tweets with 12.640 impressions
4 posts with 1.998 impressions
MORE INFO
Creation of 8 videos with 185 views
SOCIAL MEDIA:
19 tweets with 12.640 impressions 4 posts with 1.998 impressions
Debate on “Animal experimentation in science" at the Science Fest organized by the Barcelona city council.
Objective: To organize a debate to give the widest possible vision, from different aspects of animal experimentation, so that the public could form a clearer opinion on a topic so important in science and that currently generates a lot of discussion.
SOCIAL MEDIA:
8 tweets with 8.197 impressions
1 post with 581 impressions
MORE INFO
8 tweets with 8.197 impressions 1 post with 581 impressions
Participation in the project "Absolutos y relativos"
Objective: To publicise the research through the eyes of the researchers involved by recording the podcast “Drugs and mental diseases”. In this episode Dr. Patricia Robledo, researcher in the IMIM’s Neurosciences programme, explains the neuroscience and drug studies she was carrying out while telling us about his research career closely linked to psychology.
PLATFORMS WHERE IT HAS BEEN PUBLISHED: Spotify, Google Podcast, Apple Podcast, Ivoox and Spreaker
MORE INFO
Participation in the project "La Mare de la Ciència". Second season
Objective: To publicise the research through the eyes of the researchers involved by recording the podcast “Deciphering behavior and combating neurodegeneration”. In this episode Dr. Arnau Busquets, researcher in the IMIM’s Neurosciences programme, explains the studies that he is carrying out. This is the second season of the project.
PLATFORMS WHERE IT HAS BEEN PUBLISHED: Spotify, Google Podcast, Apple Podcast, Ivoox and Spreaker
MORE INFO
Open PRBB - October 8
Objective: To introduce science to the general public in order to promote scientific culture and facilitate knowledge through participation in the PRBB's Open Day. Public can visit different labs, participate in workshops or attend scientific talks.
SOCIAL MEDIA:
18 tweets with 12.195 impressions
5 stories with 6.230 impressions
MORE INFO
18 tweets with 12.195 impressions 5 stories with 6.230 impressions
Seniors week - Sofia Barat library - October 4
Objective: To participate in the Seniors week with a talk on "The brain and the passage of time" where Dr. Carla Capellades and Dr. Isabel Arnau of the Geriatrics Service of the Hospital del Mar explained the changes that occur in the brain with the passage of time and how they affect us.
SOCIAL MEDIA:
2 tweets with 500 impressions
MORE INFO
2 tweets with 500 impressions
ACTIVITIES FOR STUDENTS
Science Tuesdays - February 15
Objective: To participate in these virtual talks organized by the PRBB to bring aspects of biomedicine that affect society to students in 4th ESO and high school. Dr. Francina Fonseca, researcher of the IMIM Addictions group participated with the talk: “Addictions: Vice or disease?”
Visit of the Narcís Xifra high school students of Girona - December 20
Objective: To bring science to high school students
Activity: The researcher explains the work that his group is currently carrying out and then the students visit the facilities and the laboratory. On this occasion they visited the laboratory of Mechanisms of tumorigenesis and tumor progression group coordinated by Dr. Antonio Garcia de Herreros.
Activity: The researcher explains the work that his group is currently carrying out and then the students visit the facilities and the laboratory. On this occasion they visited the laboratory of Mechanisms of tumorigenesis and tumor progression group coordinated by Dr. Antonio Garcia de Herreros.
Attendees: 50 students
"Science Journalist” activity
Objective: To partcipate in the "Science Journalist" activity organised by the PRBB with the participation of all the centres, aimed at pupils aged between 10 and 12 years of age.
Activity: The children prepare Cancer-related questions at school and ask them live to Dr. Raúl Peña, member of the tumorigenesis and tumor progression research group at the IMIM
Activity: The children prepare Cancer-related questions at school and ask them live to Dr. Raúl Peña, member of the tumorigenesis and tumor progression research group at the IMIM
Attendees: 40 STUDENTS
Fundraising
Campaigns organised by the IMIM with the support of the Amics del Hospital del Mar Foundation for medical research have successfully funded 1,367 hours of research.
Marathon Zurich-Barcelona crowdfunding campaign
A campaign led by 10 physicians and researchers for breast cancer research
Running race crowdfunding campaign Bombers Barcelona
13 professionals and 2 firefighters running for breast cancer research.
Kilometres for ELA sport event
A 24-hour running event for ELA research.
Marina WalkTrail sport event for breast cancer research
Nordic Walking 2022 event with 419 participants supporting biomedical research.
Small donor recruitment campaigns
F2F campaigns successfully recruited 274 small donors.
Donor loyalty plan
Activities and information aimed at nurturing relationships with regular donors, including monthly newsletters.
P2P campaign to support research
Corporate and Team Building event with a fundraising goal, led by MEDIAPRO.
Project to get strategic alliances with preference partners
"Strategic alliance with Cris Contra el Cancer and alliance with the Alberto Contador Foundation for Stroke Research"
Amics de l’Hospital del Mar Foundation collaborates in breast cancer immunotherapy research
Research into cancer immunotherapy has received a significant boost thanks to a donation from the Amics de l’Hospital del Mar Foundation. In recent years, the foundation has donated the equivalent of 3,850 hours of cancer research.
More info
More info
Joaquín Arribas
Director of Hospital del Mar Medical Research Institute (IMIM) and Research Director of Hospital del Mar
"We conduct research that benefits people, our goal is to bring scientific advancements to patients."
Evaluated initiatives in patents
6
Protected + 2 PCT extensions
3
Discarted
5
Pending
Patents in Force by Programme
Number of new patents:
1
NEUROSCIENCES
1
BIOMEDICAL INFORMATICS
4
CANCER
1
TRANSLATIONAL CLINICAL RESEARCH
1
EPIDEMIOLOGY AND PUBLIC HEALTH
TOTAL
8
Number of active patents
3
NEUROSCIENCES
1
BIOMEDICAL INFORMATICS
10
CANCER
3
TRANSLATIONAL CLINICAL RESEARCH
1
EPIDEMIOLOGY AND PUBLIC HEALTH
TOTAL
18
Number of patents licensed:
1
NEUROSCIENCES
0
BIOMEDICAL INFORMATICS
2
CANCER
1
TRANSLATIONAL CLINICAL RESEARCH
0
EPIDEMIOLOGY AND PUBLIC HEALTH
TOTAL
4
Other results
An algorithm
An algorithm for the prediction of breast cancer metastasis based on the breast density of patients has been protected in front of a notary.
A know-how
A know-how (mental health app) has also been transferred to the Norwegian health system for translational and implementation in Norway.
Spin Offs
Chemotargets
The highlight of Chemotargets in 2022 was the signing, on November 17th, of a long-term deep-tech collaboration agreement with Chemical Abstracts Service, the 115-year-old division of the American Chemical Society specialized in scientific information solutions. This agreement aims to utilize Clarity® as its technological foundation for global life sciences innovation, with planned future investments to facilitate integration and expansion, covering the entire pharmaceutical R&D workflow.
DISGENET
"The new DISGENET Plus platform was launched (versions 18.0, 19.0, and 20.0).
Laura Furlong, CSO of MedBioinformatics, was ranked in the top 2% of the most cited and influential researchers in her field, according to the report from Stanford University."
Clinical guidelines
Total Clinical Practice Guidelines 72 and implemented in clinical practice 10
Clinical Guidelines 2022.pdf
Highlights
6.03.2023
Doctors Pilar Navarro and Neus Martínez, Winners of the Vanguardia de la Ciencia Award
READ MORE
22.12.2022
The European Medicines Agency selected Hospital del Mar Medical Research Institute and the Hospital del Mar to be a Data Partner of the DARWIN EU® data network
READ MORE
2.12.2022
First clinical trial of a new drug to improve the cognitive function of people with Down syndrome
READ MORE
16.11.2022
The validity of nine biomarkers for diagnosing Alzheimer's disease in daily clinical practice has been determined
READ MORE
3.11.2022
La Marató de TV3 and Catalunya Ràdio will fund six mental health research projects in which Hospital del Mar and the Hospital del Mar Medical Research Institute will take part
READ MORE
5.10.2022
Researchers discover how to overcome a treatment resistance mechanism in one of the most aggressive types of breast cancer
READ MORE
30.09.2022
The Hospital del Mar Medical Research Institute participates in the broadest genomic study on stroke to date.
READ MORE
12.09.2022
Having an imbalanced immune system increases the risk of dying from COVID-19 by almost five times.
READ MORE
11.08.2022
A new study identifies two biomarkers in the blood that better capture early signs of Alzheimer's
READ MORE
30.05.2022
Researchers Discover a Set of Poor Prognosis Markers in Patients with Colon and Rectal Cancer
READ MORE
4.05.2022
The Hospital del Mar Medical Research Institute receives a European grant of 2.5 million euros to expand knowledge of the human genome
READ MORE
19.04.2022
European Support for Validating Artificial Intelligence Tools Sensitive to Human Values
READ MORE
30.03.2022
Potential utility of a marker to personalise anti-CD20 treatment in patients with multiple sclerosis
READ MORE
14.02.2022
More than 50% of people with treatment-resistant epilepsy also suffer depression or anxiety
READ MORE
31.01.2022
Research led by the Hospital del Mar Medical Research Institute selected in the first edition of the Cancer Innova project.
READ MORE
21.01.2022
Cardiac damage in COVID-19 patients is an indicator of poor long-term prognosis
READ MORE
About us
Inaugurated in 1948 by Dr. Alexander Fleming, the Hospital del Mar Medical Research Institute (IMIM) is a center of excellence for biomedical and health research.
IMIM is part of the Parc de Salut Mar consortium, and it is made up of more than 700 professionals, with a mixed composition of IMIM researchers and clinical researchers from Hospital del MAR and other academic researchers from UPF and UAB.
IMIM has the recognition of CERCA as a Catalan Research Institute of Excellence, ISCIII as Health Research Institute and HRS4R with the HR Excellence in Research.
Its proximity to Hospital del Mar and the Campus Universitari Mar, and its location in a solid scientific ecosystem like PRBB, means that IMIM is in a privileged biomedical enclave in Barcelona.
IMIM’s translational research is carried out through five well-structured research programs: epidemiology and public health, neuroscience, cancer, biomedical informatics, and clinical translational research programs.
Our Mission
To conduct excellent translational research to be an international reference in biomedical research.
Future Challenges
Excellence in scientific activity through internationalization and attracting talent
Sustainable growth through cost-effective investment of resources and promotion of development
Seamless linkage to society through highly translational research aligned with PSMAR’s strengths
IMIM Board
President
Olga Pané
Manager of the Consorci Mar Parc de Salut de Barcelona
Secretary
Aida Pérez
Head of Legal Services, IMIM-Hospital del Mar Medical Research Institute
Members
Miguel Pera
director of the medical and healthcare area of Parc de Salut Mar
Arcadi Navarro
director of the Barcelonaβeta Brain Research Center
Assumpció Malgosa
vice-rector of research and transfer, UAB
José García Montalvo
Commissioner of Science Policy of the UPF
IMIM Foundation Board
Chair
Manel Balcells i Díaz
Minister of Health
FIRST VICE-PRESIDENT
Joaquim Nadal i Farreras
Minister of Research and Universities
SECOND VICE-PRESIDENT
Davide Malmusi
Vice-president of the Governing Council of Barcelona Mar Health Park Consortium
MEMBERS
Javier Lafuente Sancho
Rector of Universitat Autònoma de Barcelona
Oriol Amat Salas
Rector of Universitat Pompeu Fabra
Joan Gómez Pallarès
General Director for Research Ministry of Business and Knowledge
Aina Plaza Tesías
Appointed by the Ministry of Health
Olga Pané Mena, Miguel Pera, Josep Aumatell, Narcís Pérez de Puig (acting Secretary)
Appointed by the Barcelona Mar Health Park Consortium
Assumpció Malgosa Morera
Appointed by the Universitat Autònoma de Barcelona
José García Montalvo
Appointed by Universitat Pompeu Fabra
Scientific Advisory Board (SAB)
President
Xosé R Bustelo PhD
Deputy Director of the Cancer Research Center (CIC), University of Salamanca-CSIC (Salamanca, Spain)
Members
Gervaise Loirand
DR1 Inserm Team leader III "Signaling and vascular and pulmonary pathophysiology", Deputy director of the UMR Inserm 1087 / Cnrs 6291 L'Institut du Thorax. Université de Nantes. France
Gitte Knudsen
Chair, Professor, MD, DMSc. Dept. Neurology and Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Denmark
Caroline Sabin
Professor of Medical Statistics and Epidemiology. Infection & Population Health, Institute for Global Health. Faculty of Pop Health Sciences. UCL Principal Supervisor, UCL Subsidiary Supervisor. University College London, UK.
Luca Gianni
Milan, Italy. Director, Medical Oncology, Head of the New Drug Development Laboratory of Clinical Pharmacology. Ospedale San Raffaele. President, Michelangelo Foundation.
Alvis Brazma
Functional Genomics Senior Team Leader and Senior Scientist. EMBL-EBI, UK.
Research Programmes
Biomedical Informatics
Epidemiology and Public Health
Translational Clinical Research
Scientific & Technical Support
Internal Scientific and Technical Support
Platforms
Development
Digitization and IT
Fundraising
Administration
Competitive Funding
Associated partners
Trustees
Public Funders
